M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis - Wikidata - awgldk - TriplyDB

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

http://www.wikidata.org/entity/Q42572043

about

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma Cancer-Associated Myeloid Regulatory Cells Ontogeny of Tissue-Resident Macrophages Vascularisation of the central nervous system Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression Mouse models for studying angiogenesis and lymphangiogenesis in cancer Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues Macrophages: gatekeepers of tissue integrity Immune modulation of stem cells and regeneration Integration of CD45-positive leukocytes into newly forming lymphatics of adult mice.Myeloid-derived cells are key targets of tumor immunotherapy Lymphangiogenesis is required for pancreatic islet inflammation and diabetes Macrophage diversity enhances tumor progression and metastasis Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction.Macrophages form functional vascular mimicry channels in vivo Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts.Tissue factor and PAR2 signaling in the tumor microenvironment VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells.Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha.Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures Regulation of Embryonic and Postnatal Development by the CSF-1 Receptor.Hypoxia-Inducible Factor 1α Is a Critical Downstream Mediator for Hypoxia-Induced Mitogenic Factor (FIZZ1/RELMα)-Induced Pulmonary Hypertension.Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer.TGFβ1 inhibits lymphatic endothelial cell differentiation from mouse embryonic stem cells.Current views on the function of the lymphatic vasculature in health and disease Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis Macrophage metalloelastase (MMP-12) deficiency mitigates retinal inflammation and pathological angiogenesis in ischemic retinopathy.Molecular mechanisms involved in tumor repopulation after radiotherapy.Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review.Vascularity of nongynecological leiomyosarcoma depends on colony-stimulating factor 1 but not on vascular endothelial growth factor.CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis.Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells.Metchnikoff's policemen: macrophages in development, homeostasis and regeneration.VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.

P2860

Q24631455-A3C27FF5-CFB2-47A3-BAD1-2C3F4D204D30 Q26750382-A9EB6F08-B49C-4102-BDF7-AB95A9C21615 Q26781251-C14D1A35-EDE7-4FA6-874A-B315569F729F Q26801786-8984E310-BEF9-47CA-8A01-6D49427E42C8 Q26863784-7BC351B7-21AA-4FF6-A167-365BB6533CA2 Q27003898-51E4D4F9-28DF-46C0-BF27-ADC47CACCB0F Q27003907-D295D43D-10A0-4991-A7F6-57C8F3E20BE0 Q27007092-8F109694-F9E2-46E4-B30A-F8425EC49BCE Q27010686-4DBD5D80-E7E3-43E3-A60C-56A5C3C05192 Q27321396-B0276B1E-CA93-4CFC-A1F0-FDC0F9F8DD06 Q28388246-B773F722-DF84-422A-BF58-FCDD68D956C6 Q28742322-62CF9EC6-7A30-4748-B1F9-462D7EA1ECED Q29615847-68842719-73A5-43AA-B695-C9664525F24E Q30278005-A7171743-7AEC-41CD-95B4-EF7873F7B103 Q30408302-82B2F832-4C06-426F-B381-6BFB1BD98117 Q30493887-CFBDB7BF-3D1E-4609-8B77-0EE20D26E6C7 Q30496577-ED40F460-2297-4416-B56E-5EB086C77DFC Q30828304-195DAD24-6163-4AAC-A3EB-8F1859A4BA4B Q31137466-C2C423F9-297B-4377-BB41-ABA17146394C Q33592102-75E3BC7C-0398-4347-80BF-467C2B0597DE Q33615188-C4542954-2845-49E4-9813-066E0C6974E5 Q33645579-B00B902F-0E1B-47A1-AB01-CBC7FA3DA751 Q33680436-68E84A5E-6293-4B31-8F6A-2D4E7C20FDFE Q33707131-D71DF015-D16E-4A4F-A334-8F5CB6C9E86F Q33802916-452BF6FB-B564-46FB-8945-10727ECE94E6 Q33820660-727BA91F-162D-49CA-B005-0AC2D72DDCF2 Q33920050-43DAD52E-76EC-47BF-8259-208A330D0BAD Q33929607-226F8406-E56F-408E-BBBD-7D9E0750DD45 Q34000280-4A041FB9-CA96-49C3-B203-E655F52CDA4E Q34144338-FDEC53E5-DDA4-4B26-A4EE-6DE9BBC9F93D Q34164880-396B089C-94E8-41B5-8FBC-8EDAFC5A5608 Q34282386-E02834E5-E779-48A8-97C6-2D9E5C6978B8 Q34534458-3A0DEC4C-16F7-423B-9245-3177D733AFEB Q34948795-19109B12-75B8-44DC-BC2E-AD090802C607 Q35043525-37C21C70-62DB-4B17-B2D0-8E94157FC112 Q35235604-976144BC-6B87-4C62-87F3-4C860F1272F6 Q35235635-010295EA-C8BF-453A-A10D-29D6186433C3 Q35546629-94E36D8F-27E3-4EA0-BB6A-12B046C164D8 Q35577477-B0B7841B-A5E8-4CA9-B2BB-2D23D1FF24A5 Q35682284-728FB2D4-DE03-48C8-BD60-B901071A66C4

P2860

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

http://www.wikidata.org/entity/Q42572043

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

@en

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

@nl

type

label

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

@en

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

@nl

prefLabel

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

@en

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

@nl

P1433

Q42572043-7A2C8A5A-AB79-4F20-B37D-79D9327CE283

P1476

Q42572043-A2B88AD5-24EB-45BF-9EDF-B1AA9E2CF465

P2093

Q42572043-003ED100-3044-43CA-92B6-9E119B2D471D

Q42572043-7D1883C0-FF5B-4142-9CDE-C8113B970FAC

Q42572043-920C614D-00E1-4129-A2FF-3D51B4EF0FB2

Q42572043-D705770D-F44C-417B-AA7B-30C449366EBD

Q42572043-DD33C2AD-9925-4131-BC6F-F4BE1B969925

Q42572043-E18E5A4F-EFBB-4E78-AE5E-42DE82C5FFA8

Q42572043-FD65C8F6-A3BB-40C0-B152-0A1D31E0161D

P2860

Q42572043-040109E6-6039-465C-85FC-5700E5314B5E

Q42572043-04B2DA10-4058-4212-B372-FB8B1B654AAC

Q42572043-21486A53-1A41-40B3-915C-FEC03B40A0BA

Q42572043-2454D038-02E8-4AA5-A650-32104A8C3DBB

Q42572043-2837C606-7B2C-446E-839E-6E47A328A5B2

Q42572043-32D2C613-1EEB-4A47-A62A-85EE6F3A4C9A

Q42572043-336BB17E-DB95-43F3-8C36-F6F7747CA38D

Q42572043-34E7D185-53A0-4379-84B0-F6AD023E6379

Q42572043-3740EDB9-C30B-4AC9-9189-0093DABC8029

Q42572043-37D818D8-362A-439E-8885-50D167F6DBAA

P304

Q42572043-46037DDD-0B5A-4F40-97A7-F7532065D8D1

P31

Q42572043-4320D9BD-5EE5-43C8-A7A6-732F50618F2E

P356

Q42572043-3C3F0402-D58A-4755-A6B9-3A2DBA65DCAE

P407

Q42572043-5E841D67-B785-43EA-A27E-6A91CB67AB5D

P433

Q42572043-5258A873-5F62-4DEA-91D8-844ACF31B89B

P478

Q42572043-CDD9B1C8-B93A-4121-833B-6344D62543B7

P50

Q42572043-31B0A3C5-4BD6-4130-B28A-B9D7535111BB

P577

Q42572043-E97CA758-C4F0-4284-8464-E5CC19D1B660

P5875

Q42572043-EB710C91-01F2-4576-97EE-4152D4C12732

P698

Q42572043-9C13F35E-C62B-481E-B340-2AFA6B06ECD8

P921

Q42572043-591A6CF6-CD4A-4883-A15F-B4FD72183267

P932

Q42572043-8C34DEE2-82B4-4D67-8A56-307ECD73D4A3

P356

P1433

Journal of Experimental Medicine

P1476

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

@en

P2093

Hideyuki Saya

http://www.w3.org/2001/XMLSchema#string

Hiroaki Ohno

http://www.w3.org/2001/XMLSchema#string

Kazuo Kishi

http://www.w3.org/2001/XMLSchema#string

Keiyo Takubo

http://www.w3.org/2001/XMLSchema#string

Masabumi Shibuya

http://www.w3.org/2001/XMLSchema#string

Takatsune Shimizu

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Kubota

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

VEGF-Trap: a VEGF blocker with potent antitumor effects.

The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model

WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

Angiogenesis in life, disease and medicine

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia

Angiogenesis as a therapeutic target

How matrix metalloproteinases regulate cell behavior

P304

1089-1102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20081605

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

206

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24365846

http://www.w3.org/2001/XMLSchema#string

P698

19398755

http://www.w3.org/2001/XMLSchema#string

P921

lymphangiogenesis

P932

2715025

http://www.w3.org/2001/XMLSchema#string